Skip Navigation
  • Text Size: A A A
  • Print
  • Email
  • Facebook
  • Tweet
  • Share

Dr. Hanna's Notes on Blood Safety - Day 1 CFSAC Meeting

Since 1989, NHLBI has been and continues to monitor the blood supply regularly through its Retrovirus Epidemiology Donor Study. Currently they are finishing up REDSII in 2010 and will begin REDSIII in 2011. Anytime a new finding arises, the supply for the general donor population is tested for its prevalence to help determine if it is even blood borne. Currently, Dr. Michael Busch at the Blood Systems Research Institute ( is doing this for XMRV; NHLBI will pursue according to usual practice.

NCI is preparing a Q&A sheet to address the issues that arise from these findings on XMRV. Also relevant are the following postings on prostate cancer:

1)      Two Cancer Bulletin articles on reports suggesting XMRV might be associated with some prostate cancers:  


2)      A page on DCEG’s Web site about the association with prostate cancer:

3)      The PDQ Genetics of Prostate Cancer Summary, under “Hereditary Prostate Cancer 1”:

Please visit the Web site of the Division of Blood Diseases and Resources (DBDR), National Heart, Lung, and Blood Institute (NHLBI).

Articles referenced in the discussion:

Murphy, E., & Glynn, S. (1999). Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic.. Archives of Internal Medicine, 159(13), 1485. Retrieved from Academic Search Premier database.

Hjalgrim, H., Edgren, G., Rostgaard, K., Reilly, M., Trung Nam, T., Titlestad, K., et al. (2007). Cancer Incidence in Blood Transfusion Recipients. JNCI: Journal of the National Cancer Institute, 99(24), 1864-1874. doi:10.1093/jnci/djm248.

Edgren, G., Hjalgrim, H., Reilly, M., Tran, T., Rostgaard, K., Shanwell, A., et al. (2007). Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study. Lancet, 369(9574), 1724-1730. Retrieved from Academic Search Premier database.